课题基金 / 基金详情

Large genomic deletions of a novel oncolytic Vaccinia Virus increase safety, efficacy and cancer immunogenicity

Large genomic deletions of a novel oncolytic Vaccinia Virus increase safety, efficacy and cancer immunogenicity
新型溶瘤痘苗病毒的大基因组缺失提高了安全性、有效性和癌症免疫原性
批准号：
391665
负责人：
Pelin Adrian
金额：
$0.05万
依托单位：
Ottawa Hospital Research Institute
依托单位国家：
加拿大
项目类别：
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-08-01 至 2019-08-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=391665&lang=en
关键词：
Ics Travel Awards

项目摘要

项目成果

Pelin Adrian的其他基金

相关文献

中文摘要
翻译
随着现有化疗治疗的不可预测的成功，对新颖有效的癌症治疗有明确的需求。溶瘤病毒（OV）是能够靶向并破坏癌细胞的病毒。与化疗相反，
英文摘要
With the unpredictable success of available chemotherapy treatments, there is a clear demand for a novel and effective cancer treatment. Oncolytic viruses (OVs) are viruses that are able to target and destroy cancer cells. In contrast to chemotherapy whic
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigating Vaccinia virus-host interactions to develop a cancer-selective virotherapy
Large genomic deletions of a novel oncolytic Vaccinia Virus increase safety, efficacy and cancer immunogenicity
Evaluating various Vaccinia virus strains as oncolytic engines through Next Generation Sequencing of co-infections